Pompetravaini’s Post

As a qualified lab sampler, I can tell you for certain that this platform can add value to you compliance/lab workflows. I've seen a lot of approaches and there's often too many opportunities for mistakes. Check it out!

❗Effective immediately, Amjevita will no longer be covered under #CVS Caremark's standard #formulary. Instead, Hyrimoz and an unbranded #biosimilar will be the preferred options. Hyrimoz and the unbranded biosimilar are both clinically equivalent to #Humira, available at a lower cost.💰💉 https://lnkd.in/gK3i-Xyu

🌍 Exciting News on the Impact of Biosimilar Competition for Alpha Inhibitor Biosimilars in the EU 🌍 🏷 The NAVLIN Price & Access Data NEWS has recently published an insightful article* shedding light on the influence of competition among Alpha Inhibitor biosimilars in the European market and its direct correlation to price reductions. The study found that upon the entry of the first biosimilar in the market, there was a notable price reduction of up to 14%. However, the real shift occurred with the introduction of the second biosimilar, leading to a significant price reduction of up to 27%. 📌 Notably, the research conducted by our team at NAVLIN Price & Access Data extends beyond these initial findings. We delved deeper and observed a critical turning point in the competition landscape. The true transformation arises when the third competitor enters the market. At this milestone, the originator faces the risk of being edged out of the tenders market, primarily due to the lowest price offered by the competitors. It is essential to recognize that a substantial majority of tenders in the Life Science sector are awarded to either a single company or up to three companies. This makes the "magic number" for biosimilar competition, three. ⏳ The time it takes for three competitors to enter a market can vary based on numerous factors, including country-specific considerations. However, one constant trend we have discovered in our research is that the originator faces exclusion from tenders, sometimes entirely, once the third competitor gains a foothold in the market. Moreover, our data showcases that price reductions can reach a remarkable 70% within 3-5 years from the Loss of Exclusivity (LoE) date, contingent on various factors, including geographical elements. The LoE process requires delicate handling and meticulous planning and preparation. At NAVLIN Price & Access Data, we are fully equipped to support your journey through this process, ensuring smooth navigation of pricing and data challenges, including LoE preparedness. Reference: cited article https://bit.ly/3OCtUdj

 Soak up the sun and A2A's latest updates in our June RXRoundup! #A2APharma #SDVOS

The last thing you need when working on a big proposal with a tight deadline is a blocked nose interrupting your workflow. Thankfully, we have the perfect solution to your problem. Amuco 600 effectively clears excess phlegm and mucus, helping you breathe easier. Plus, it's non-sedating, so your workflow stays uninterrupted as you power towards that deadline. #amuco600 #amucomazing #nomoremucus #clearthefuzz #austellpharmaceuticals

2024 is The Year for tackling Drug Mix by answering "What Drugs Do I Cover--And How?" Comparative Effectiveness Research is the answer used by all of our peer nations, which is one (of many) reasons they spend so much less on drugs than we do. If you want a refresher on what Comparative Effectiveness Research is and how it can help self insured employers and their advisors save on specialty, generic, non-specialty brands, and even high cost Cell/Gene therapies (with a better clinical benefit), I encourage you to check out this 3-minute refresher video courtesy of Chris Fisher and BenefitsAlly. https://lnkd.in/eJSxpfSJ

Using nothing but Oreo and applesauce, Nick Allan and Joris van der Heijden explore a cutting-edge assay technique and its applications in drug-device combinations. Watch and learn more about an exciting analytical methodology. #medtech #bioservices #assay 

the goal of improving outcomes and controlling cost is available now not a vision for the future.

Happy Friday! Indian #Pharma Firms Zoom in on #Anti-obesity Drug Development Amid Surge in #Ozempic Sales Indian pharma firms are developing anti-obesity drugs in response to the increasing demand caused by the rising prevalence of obesity and the success of #Ozempic (semaglutide). Ozempic is expected to reach $12.5 billion in sales by 2023. Pharma Majors like Dr. Reddy's, Lupin, Zydus, and Sun Pharma are actively working on #anti-obesity drugs due to the limited availability of such medications in the #Indian market. Market reports indicate that the weight management market in India is projected to reach Rs 2,762.7 crore by 2028, with a significant growth rate of 10.6%. Indian pharma companies are conducting studies and forming alliances to address the growing anti-obesity market. Continue reading on https://lnkd.in/dbQ67H5j

Here's how when the world faced its toughest Global Pandemic, Fevicol emerged as a true adhesive, binding hearts and minds together with an extraordinary campaign that left an indelible mark on everyone! 🌍 Follow us for more of such Content! . . #fevicol #kaushikdigibuzz #howfevicoldidit #casestudy #marketinnggenious